JPWO2022254371A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022254371A5
JPWO2022254371A5 JP2023574315A JP2023574315A JPWO2022254371A5 JP WO2022254371 A5 JPWO2022254371 A5 JP WO2022254371A5 JP 2023574315 A JP2023574315 A JP 2023574315A JP 2023574315 A JP2023574315 A JP 2023574315A JP WO2022254371 A5 JPWO2022254371 A5 JP WO2022254371A5
Authority
JP
Japan
Prior art keywords
iii
compound
formula
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520630A5 (https=
JP2024520630A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/055154 external-priority patent/WO2022254371A1/en
Publication of JP2024520630A publication Critical patent/JP2024520630A/ja
Publication of JPWO2022254371A5 publication Critical patent/JPWO2022254371A5/ja
Publication of JP2024520630A5 publication Critical patent/JP2024520630A5/ja
Pending legal-status Critical Current

Links

JP2023574315A 2021-06-04 2022-06-02 ブルトン型チロシンキナーゼの阻害剤及びその使用方法 Pending JP2024520630A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
US63/196,843 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (3)

Publication Number Publication Date
JP2024520630A JP2024520630A (ja) 2024-05-24
JPWO2022254371A5 true JPWO2022254371A5 (https=) 2025-05-28
JP2024520630A5 JP2024520630A5 (https=) 2025-05-28

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574315A Pending JP2024520630A (ja) 2021-06-04 2022-06-02 ブルトン型チロシンキナーゼの阻害剤及びその使用方法

Country Status (14)

Country Link
US (1) US20230013755A1 (https=)
EP (1) EP4346834A1 (https=)
JP (1) JP2024520630A (https=)
KR (1) KR20240019214A (https=)
CN (1) CN117412753A (https=)
AU (1) AU2022284369A1 (https=)
BR (1) BR112023025459A2 (https=)
CA (1) CA3220015A1 (https=)
CL (2) CL2023003564A1 (https=)
IL (1) IL308951A (https=)
JO (1) JOP20230310A1 (https=)
MX (1) MX2023014435A (https=)
TW (1) TW202317127A (https=)
WO (1) WO2022254371A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008042A2 (pt) 2012-10-11 2017-07-04 Pharmacyclics Inc diagnósticos complementares para terapia com inibidor de quinase da família tec
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Similar Documents

Publication Publication Date Title
TWI910423B (zh) 用於治療細胞介素相關之病症之jak1路徑抑制劑
AU2016204396B2 (en) Methods of treatment using selective Bcl-2 inhibitors
JP2024133475A5 (https=)
JP2024133474A5 (https=)
JP2022141835A5 (https=)
JP6824906B2 (ja) 併用療法
JP2023552452A (ja) 白斑治療用のjak1経路阻害薬
JPWO2022254371A5 (https=)
EP3713576A1 (en) Methods for cancer therapy
JP2021530440A5 (https=)
JP2018522049A5 (https=)
JP5945863B2 (ja) 腎細胞がん治療剤
TWI403509B (zh) 一種用以治療癌症之藥學組合物
JPWO2020023324A5 (https=)
JP2007518768A (ja) 有機化合物の組み合わせ物
JP2009511535A (ja) 5−(2−クロロフェニル)−1,2−ジヒドロ−7−フルオロ−8−メトキシ−3−メチル−ピラゾロ[3,4−b][1,4]ベンゾジアゼピン
JPWO2020037152A5 (https=)
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
JPWO2021245280A5 (https=)
RU2024105413A (ru) Композиции для применения в лечении в-клеточных злокачественных опухолей
JPWO2022117477A5 (https=)
JPWO2022206929A5 (https=)
JP2025541662A (ja) カピバセルチブ及びベネトクラクスの治療用組み合わせ
HK40093857A (zh) 联合治疗
RU2025106876A (ru) Терапевтические комбинации, содержащие ингибиторы убиквитин-специфической процессирующей протеазы 1 (usp1) и селективные ингибиторы parp1